While I don't doubt Hoskuld's word, I think his evaluation of the company's choice leaves out some historical context. Missling was holding back on trial sizes, etc., not simply because there was some uncertainty about outcome, but also because a poorly placed large bet would have threatened the continued existence of the company. There was no large cash reserve at the time these decisions were being made. At the best, Anavex would have suffered massive dilution. So what Missling actually did now looks pretty good.
Market Data 
Markets 
AI
